NurExone Biologic Extends Global Reach with Presentations at Industry-Leading Conferences
12 sept. 2024 16h04 HE
|
NurExone Biologic Inc
NurExone Biologic Enhances Visibility in Pharmaceutical Industry with Technological Presentations at Major Global Events
Crescendo Biologics to present at the 2024 AACR Annual Meeting
06 mars 2024 07h00 HE
|
Crescendo Biologics
Crescendo Biologics to present at the 2024 AACR Annual Meeting Cambridge, UK, 6 March 2024 – Crescendo Biologics Ltd (Crescendo), a clinical stage, immuno-oncology company developing novel, targeted...
Amphista Therapeutics announces new data demonstrating in vivo efficacy and CNS activity of its mechanistically differentiated targeted protein degraders
24 janv. 2024 07h00 HE
|
Amphista Therapeutics
PRESS RELEASE Amphista Therapeutics announces new data demonstrating in vivo efficacy and CNS activity of its mechanistically differentiated targeted protein degraders First...
Amphista Therapeutics announces new data demonstrating in vivo efficacy and CNS activity of its mechanistically differentiated targeted protein degraders
24 janv. 2024 03h00 HE
|
Amphista Therapeutics
PRESS RELEASE Amphista Therapeutics announces new data demonstrating in vivo efficacy and CNS activity of its mechanistically differentiated targeted protein degraders First...
Statement from Dr. Jonathan Milner on the suspension of the “Vote AGAINST” campaign
01 nov. 2023 07h00 HE
|
Jonathan Milner
Statement from Dr. Jonathan Milner on the suspension of the “Vote AGAINST” campaign CAMBRIDGE, England, 1 November 2023 - Jonathan Milner, the founder and one of the largest investors in Abcam plc...
Arecor: Business Update
20 juil. 2023 07h00 HE
|
Arecor Therapeutics plc
Arecor Therapeutics plc(“Arecor” or the “Group”) BUSINESS UPDATE Strong pipeline of revenue-generating collaborations with major pharmaceutical and biotech companies with further deals anticipated...
Coherus to Acquire Surface Oncology
16 juin 2023 07h01 HE
|
Surface Oncology, Inc.
– Surface acquisition and potential toripalimab approval will transform Coherus into an I-O company with multiple next-generation immunotherapies in clinical development funded by growing revenues – ...
OBSS CodeMaster coding contest continues with Cambridge after Oxford
28 mars 2023 05h00 HE
|
OBSS TEKNOLOJI ANONIM SIRKETI
Business simulation coding contest takes place in world-class universities in the UK: Oxford, Cambridge and Imperial College, offering €30,000 grand prize Top 3 Oxford students received their prizes...
Surface Oncology Reports Financial Results and Corporate Highlights for Fourth Quarter and Full Year 2022
09 mars 2023 07h00 HE
|
Surface Oncology, Inc.
SRF388 clinical program advancing well; updated clinical data expected in the first half of 2023 First patient dosed in a Phase 1/2 study evaluating SRF114, a potential best-in-class anti-CCR8...
OBSS CodeMaster expands into the UK, coding contest takes place in Oxford & Cambridge with €30,000 grand prize
03 mars 2023 07h00 HE
|
OBSS TEKNOLOJI ANONIM SIRKETI
Software development and technology company OBSS Technology, conducts CodeMaster coding contest with a legacy of more than 10 years. On its 11th year, OBSS CodeMaster online coding contest expands...